The Platform Technology Designation Program for Drug Development Guidance for Industry of the United States and its implications for the regulation of cell and gene therapy in China

MA Qiao-ning, SUN Tan-lin, WANG Wen-ya

PDF(725 KB)
PDF(725 KB)
Chinese Journal of New Drugs ›› 2025, Vol. 34 ›› Issue (4) : 337-340. DOI: 10.20251/j.cnki.1003-3734.2025.04.001

The Platform Technology Designation Program for Drug Development Guidance for Industry of the United States and its implications for the regulation of cell and gene therapy in China

    {{javascript:window.custom_author_en_index=0;}}
  • {{article.zuoZhe_EN}}
Author information +
History +

HeighLight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

QR code of this article

Cite this article

Download Citations
{{article.zuoZheEn_L}}. {{article.title_en}}. {{journal.qiKanMingCheng_EN}}. 2025, 34(4): 337-340 https://doi.org/10.20251/j.cnki.1003-3734.2025.04.001

References

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}
{{article.copyrightLicense_en}}
PDF(725 KB)

Accesses

Citation

Detail

Sections
Recommended

/